

1 / 12




FIG. 1

FIG. 2A





FIG. 2B





FIG. 2C


2 / 12

**A. WHEN THE DRUG TARGET
IS MONOMERIC**




GENETIC: Drug^R mutations will
usually be dominant

CONSEQUENCES: Resistant viral
progeny are easily selected
in presence of drug



**B. WHEN THE DRUG TARGET
IS OLIGOMERIC**



GENETIC: Drug^R mutations will
usually be recessive

CONSEQUENCES: Resistant viral
progeny are less likely to be
selected in presence of drug




FIG. 3

3 / 12

FIG. 4






FIG. 5



4 / 12

FIG. 6



5 / 12

FIG. 7

5.20 RNA binding





FIG. 8


Poly A / dt₁₆ extension



6 / 12

FIG. 9

Effect of 3D Dilution on Activity



7 / 12

FIG. 10
Modeling RNA Into the Poliovirus Oligomer






FIG. 11



9 / 12

FIG. 12




10 / 12

FIG. 13

25 μ M peptide



No peptide






FIG. 14

12 / 12

FIG. 15

Bgal of Heterol. Int II
(LexPolio 3D d65 vs. HRV (1-136))

